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A previous study has demonstrated a significant decrease in the TCRζ gene expression level in chronic myeloid
leukemia (CML); thus, we further investigated the expression of TCRζ-regulating factors, the distribution of the TCRζ
3' untranslated region (3'-UTR) splice variants, and the expression level and correlation of the alternative splicing
factor/splicing factor 2 (ASF/SF-2), FcεRIγ and ZAP-70 genes. TCRζ 3'-UTR splice variants were identified in peripheral
blood mononuclear cells (PBMCs) from 14 healthy individuals, 40 patients with CML and 22 patients with CML in
complete remission (CML-CR) by RT-PCR. The expression level of the TCRζ, FcεRIγ, ASF/SF-2 and ZAP-70 genes was
analyzed by real-time quantitative PCR. While the expression of TCRζ gene in the CML group was significantly lower
than that in the healthy individual and CML-CR groups, a significantly higher expression of the FceRIγ and ASF/SF-2
genes was found in the CML group. Two types of splicing forms were detected in all of the healthy individual
CML-CR cases: wild type (WT) TCRζ 3'-UTR and alternatively splieced (AS) TCRζ 3'-UTR which have been alternatively
splieced in the WT TCRζ 3'-UTR . However, 35% of the CML cases contained only the wild type TCRζ 3'-UTR isoform.
Based on the TCRζ 3'-UTR isoform expression characteristic, we divided the patients with CML into two subgroups:
the WT+AS- CML group, containing patients that express only the wild type TCRζ 3'-UTR, and the WT+AS+ CML
group, which contained patients that expressed two TCRζ 3'-UTR isoforms. A significantly different ASF/SF-2 and
FcεRIγ gene expression pattern was found between the WT+AS- and WT+AS+CML groups. We concluded that
defective TCRζ expression may be characterized in the WT+AS-and WT+AS+CML subgroups by the different gene
expression pattern. The overexpression of ASF/SF2, which alternatively splices the TCRζ 3’-UTR, is thought to
participate in feedback regulation. The characteristics of TCRζ 3'-UTR alternative splicing may be a novel
immunological marker for the evaluation of the CML immune status.
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Chronic myeloid leukemia (CML) is a clonal hematopoietic
stem cell disease that is characterized by the Philadelphia
chromosome (Ph), which is generated by the reciprocal
translocation t(9;22)(q34;q11) that results in the fusion of
the c-abl oncogene 1 (ABL1) with the breakpoint cluster
region (BCR) gene [1]. T cell immunodeficiency including
thymic output function, abnormal T cell receptor (TCR)
repertoire expression and, in part, abnormal TCR signal* Correspondence: yangqiuli@hotmail.com
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reproduction in any medium, provided the ortransduction, such as that involving the TCRζ chain is
found in patients with CML [2-6], and T cell function
becomes suppressed as the disease progresses in some
patients.
The TCR/CD3 complex plays a central role in T cell
activation. This complex comprises of two chains, αβ or
γδ, these chains are noncovalently associated with CD3
subunits, which include four transmembrane proteins:
CD3γ, CD3δ, CD3ε and CD3ζ (also referred to as TCRζ).
These subunits are known to form three distinct dimers,
CD3γε, CD3δε, and CD3ζζ, to mediate TCR signal trans-
duction [7-10]. There are four tyrosine kinase families
involved in TCR signal transduction including the Csk,
Src, Tec, and ZAP-70 (CD3 zeta chain associated protein
kinase 70 kDa) kinase families [11]. ZAP-70 is a cytosolic. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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following TCR stimulation and binds to phosphorylated
TCRζ immunoreceptor tyrosine-based activation motifs
(ITAMs); it plays a critical role in activating downstream
T cell signal transduction pathways following TCR engage-
ment [11]. There is evidence that the Fce receptor type Iγ
(FcεRIγ) chain, which is a member of the TCRζ chain pro-
tein family and a component of the high-affinity IgE recep-
tor, can replace a functionally deficient TCRζ chain and
facilitate TCR/CD3 complex-mediated signaling [12,13].
The absence of the TCRζ chain not only influences the
TCR expression on the cell membrane and the number
of single positive (i.e., CD4+ or CD8+) circulating T cells,
it also impairs the proliferative response and the mature
T cell activation level. T cells from patients with leukemia
are functionally impaired, and this is related to decrease
TCRζ chain expression [2,3,5,14]. Recently, we has
reported the expression pattern of the four CD3 genes in
patients with AML and CML [2,4,5,15], and it has been
reported that the aberrant TCRζ chain expression found
in the T cells of patients with systemic lupus erythemato-
sus (SLE) may be associated with the decreased stability
and translation of a TCRζ mRNA with an alternatively
spliced 3'-untranslated region [16]. However, the mecha-
nism of TCRζ deficiency in T cells in patients with cancer
remains unclear.
The TCRζ gene spans 31 kb in the chromosome
1q23.1 locus and has eight exons that are separated by
introns ranging from 700 bp to greater than 8 kb
[17,18]. The TCRζ mRNA is a 1,472 kb spliced product
of the eight exons with a 492 bp coding region and a
long downstream 906 bp 3'-untranslated region (UTR),
which is encoded by exon VIII [19]. The stability of the
TCRζ mRNA is mainly influenced by the downstream 3’
untranslated region and poly A tail. The 906 bp TCRζ
3'-UTR has several polyadenylation sites. Exon VIII
comprises 20 amino acids of the carboxy-terminus and
the 3'-UTR of TCRζ chain. Recently, it has been
reported that there are several TCRζ chain isoforms with
different 3'-UTR nucleotide sequences in mouse T cells
[20]. The activation of alternative splicing within the
3'-UTR through two internal (5' and 3') splice sites
results in a splice deletion of 562 bases (nucleotides
672–1233), leading to the generation of a 344 bp alter-
natively spliced (AS) variant [21]. The 344 bp AS TCRζ
isoform lacks two critical regulatory adenosine/uridine-
rich elements (ARE) and a translation regulatory se-
quence. The stability and translation of this isoform are
significantly lower than that of the 906 bp WT TCRζ
isoform; consequently, the relative amount of TCRζ pro-
tein generated by the AS isoform is significantly lower
than that from the WT isoform [22,23].
T cells from healthy individuals predominantly express
the wild type (WT) isoform, whereas an increased level ofthe AS isoform was reported in T cells from SLE patients
[23]. Frequent mutations/polymorphisms and aberrant
splicing of the downstream 3'-UTR may affect the stability
and/or transport of the TCRζ chain mRNA, leading to its
downregulation in SLE T cells [23]. Although differential
expression of the TCRζ 3'-UTR isoforms contributes to
differential TCRζ protein expression levels, the factor(s)
regulating the alternative splicing of the TCRζ 3'-UTR is
unknown [19].
Alternative splicing is a powerful gene regulation
mechanism that results in the generation of numerous
transcripts and proteins from a single gene [24]. Splice
site selection is regulated by cis-acting elements such as
intronic and exonic splicing enhancer and silencer
sequences, respectively [25,26]. Alternative splicing fac-
tor/splicing factor 2 (ASF/SF2) is a prototypical SR pro-
tein that was originally identified in HeLa nuclear
extract as a factor required to reconstitute splicing in
S100 cellular extract [27,28] and influence alternative
splicing site selection in a concentration-dependent
manner [28,29]. ASF/SF2 acts early during spliceosome
assembly and participates in multiple steps during con-
stitutive splicing and the regulation of alternative spli-
cing by interacting with the pre-mRNAs and/or other
splicing factors [28,30,31]. ASF/SF2 regulates the alter-
native splicing of eukaryotic genes such as caspase-9
and the T cell differentiation marker CD45 [19,32,33].
Recently, the involvement of ASF/SF2 in the post-
transcriptional regulation of TCRζ was described in T
cells from patients with SLE. ASF/SF2 binds to the 3'-
UTR of TCRζ and regulates the shift in alternative spli-
cing from the AS to the WT isoform and regulates
TCRζ protein expression [19].
Based on our previous finding that the TCRζ chain
gene expression level was significantly decreased in
CML, we further investigated the expression pattern of
the TCRζ regulating factors TCRζ 3'-UTR and ASF/SF-2,
as well as the expression level and correlation of FcεRIγ
and ZAP-70, to evaluate the ASF/SF-2 regulating effects
of TCRζ 3'-UTR formation.
Materials and methods
Samples
Forty newly diagnosed, untreated chronic phase CML
patients, including 27 males and 13 females (13–71 years
old; median age: 44 years), and 22 patients with CML
complete remission ( 16 cases after allo-HSCT and 6
cases after imatinib therapy) were included in this study
[6]. The BCR-ABL fusion gene was detected in all sam-
ples by RT-PCR. Fourteen healthy individuals including
8 males and 6 females (23–53 years old; median age:
28.5 years) served as controls. Peripheral blood mono-
nuclear cells (PBMCs) were isolated from heparinized
venous blood by Ficoll-Paque gradient centrifugation.
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lines of the Medical Ethics Committee of the Health
Bureau of the Guangdong Province in China.
RT-PCR for TCRζ 3′-UTR amplification
Total RNA was isolated from the PBMC samples using
the Trizol reagent according to the manufacturer’s proto-
col (Invitrogen, Carlsbad, CA, USA). First-strand cDNA
was synthesized using the random hexamers and reverse
transcriptase in the Superscript II Kit (PowerScript Re-
verse, BD, San Jose, CA, USA) according to the manufac-
turer’s instructions. The primers for amplification of the
TCRζ 3'-UTR and the β2-microglobulin (β2M) gene,
which was used as a control, are listed in Table 1. RT-PCR
amplification of the TCRζ 3'-UTR was performed as pre-
viously described by Nambiar et al. [23].
Real-time quantitative reverse transcription–polymerase
chain reaction (qRT–PCR)
The expression level of the TCRζ, FcεRIγ, ASF/SF-2,
ZAP-70, and β2-microglobulin (β2M) genes was deter-
mined by SYBR Green I real-time PCR. Briefly, PCR was
performed in a 20 μL total volume that contained 1 μL
of cDNA, 9 μL of 2.5× SYBR Green I mix (Tiangen,
Beijing, China), and 10 μmol/L primer pairs. After an
initial denaturation at 95°C for 3 min, 45 cycles consisting
of the following procedure was performed using an MJ Re-
search DNA Engine Opticon 2 PCR cycler (BIO-RAD,
USA):10 s at 95°C, 30 s at 64°C for β2M and ASF/SF-2,
60°C for TCRζ and ZAP-70, and 40 s at 60°C for FcεRIγ.
The relative amount of the genes of interest and the
β2M reference gene was measured in two independent
assays. The data are presented as the relative expression
of the genes of interest relative to the internal control
gene as determined by the 2(−ΔΔCT) method [2,34]. Ad-
ditionally, the specific amplification of the PCR products













β2M-r CACTCAATCCAAATGCGGCAelectrophoresis. The real-time PCR primers used for all
of the gene amplifications were synthesized by Shanghai
Biological Engineering Technology Services Co., Ltd.
(Table 1).
Statistical analysis
Univariate analyses were performed using the Mann–
Whitney test to compare the means of the differences in
the mRNA expression between the CML and healthy
control groups. Pearson correlation and linear regres-
sion analyses were used to estimate the correlation be-
tween age and the mRNA level of the different genes in
the different samples using the SPSS 11.5 statistical soft-
ware. A difference with a P < 0.05 was considered statis-
tically significant.
Results
TCRζ3′-UTR isoforms in CML
It has been reported that two types of spliceosomes could
be found on the TCRζ 3'-UTR [19,23]. In this study, the
alternatively-spliced TCRζ 3'-UTR (344 bp) and the wild
type TCRζ 3'-UTR (906 bp) could be detected in the same
PCR reaction for all healthy individual and CML complete
remission (CML-CR) samples (Figure 1). Both PCR pro-
ducts were cloned and sequenced, and the sequence was
confirmed by comparison with the sequence found in the
NCBI GenBank (data not shown). Both TCRζ 3'-UTR iso-
forms were also identified in all CML-CR patient samples;
however, 35% of the CML cases (14 cases) contained only
the wild type TCRζ 3'-UTR (906 bp), and this was signifi-
cantly different from the healthy individual and CML-CR
groups (p < 0.001, p < 0.001).
Characteristic expression of ASF/SF-2 in CML
The ASF/SF-2 expression level was quantified by real-
time PCR [35]. Although there was only one peak at
83.5°C in the melting curve analysis (Figure 2), two PCRAssociation number Product size
NM_000734.3 906 bp/344 bp





Figure 1 TCRζ 3'-UTR PCR amplification in healthy individual
and CML samples. Two splice forms, wild type TCRζ 3'-UTR (906 bp)
and alternatively spliced TCRζ 3'-UTR (344 bp), could be detected in
healthy individuals (lanes 1 and 2), patients with CML-CP (lane 3 and 4)
and patients with CML-CR (lane 5). Thirty-five percent of the CML cases
contained only the wild type TCRζ 3'-UTR isoform (lane 3). Lane 6 is an
100 bp DNA ladder.
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gel electrophoresis (Figure 2). Both of the PCR products
were cloned and sequenced, and two specific ASF/SF-2
transcripts were identified by comparison of the
sequences in the NCBI GenBank (Figure 3). The 273 bp
product was identified as ASF/SF-2 transcript 1, and the
473 bp product was identified as ASF/SF-2 transcript 2
[35]. Thus, the ASF/SF-2 expression level represented
the total expression level of all of the ASF/SF-2 tran-
scripts in this study.Figure 2 Melting curve and agarose gel analysis of ASF/SF-2 gene ex
SYBR Green I real-time PCR. B: The ASF/SF-2 PCR products were analysis by
samples from the healthy control, CML-CP and CML-CR samples, respectiveExpression pattern of the ASF/SF-2, TCRζ, ZAP-70 and
FcεRIγ genes in CML
The expression level of the TCRζ, FcεRIγ, ASF/SF-2,
ZAP-70 genes was determined by real-time PCR using
the SYBR Green I technique and quantitatively assessed
by comparison with the β2M reference gene using
cDNA from PBMCs collected from CML, CML-CR and
healthy control samples. Each of the four genes could be
detected in every sample. To establish proper real-time
quantitative PCR reaction conditions, we used diluted
Molt-4 cDNA to make relative standard curves. The
results demonstrated that the high amplification effi-
ciency of the four targeted genes was successful and
consistent with that of the β2M reference gene. In
addition, the specific amplification of the PCR products
was confirmed by melting curve and agarose electro-
phoresis analysis. A single melting curve peak and the
expected PCR products were confirmed, the PCR pro-
ducts of all of the genes were randomly selected and
sent for sequencing, and the sequencing results were
confirmed by BLAST analysis to compare with data in
GenBank (data not shown).
The expression level of the TCRζ, FcεRIγ, ASF/SF-2
and ZAP-70 genes in PBMCs from CML, CML-CR andpression. A: Amplification and Melting curve of the ASF/SF-2 gene by
agarose gel electrophoresis. M: 100 bp DNA ladder, lanes 1–3:
ly.
Figure 3 A: A schematic view of ASF/SF-2 gene bearing the isoform 1 (bottom) and 2 (top). B: Sequence of the ASF/SF-2 transcript isoform
2 PCR product. The box indicates the 200 bp sequence that was cut in transcript isoform 2, and the gray indicates the PCR primer.
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the TCRζ gene in the CML group was significantly lower
than that in the healthy control and CML-CR groups
(p = 0.027,p < 0.001), while a significantly higher level
of FceRIγ (p = 0.001, p < 0.001) and ASF/SF-2(p = 0.002,
p < 0.001) gene expression was found in the CML
chronic phase (CML-CP) group.
The expression characteristics of the TCRζ, FcεRIγ, ASF/SF-2
and ZAP-70 genes are related to TCRζ 3'-UTR spliceosome
To evaluate the effect of the alternatively spliced TCRζ
3'-UTR on the expression and regulation of the TCRζ
chain and its related genes according to TCRζ 3'-UTR
spliceosome characteristics, patients with CML were
divided in two subgroups: patients who only expressed
the wild type TCRζ 3'-UTR (the WT+AS-CML group),
and patients who expressed both TCRζ 3'-UTR forms
(the WT+AS+CML group). When the expression level of
the TCRζ, FcεRIγ, ASF/SF-2 and ZAP-70 genes wascompared between both groups, a significantly higher
level of ASF/SF-2 and FcεRIγ gene expression was found
in the WT+AS-CML group (p = 0.014, p = 0.005), and the
level of TCRζ and ZAP-70 gene expression was approxi-
mately two-fold higher in the WT+AS-CML group; how-
ever, there was no significant difference in the expression
of thses genes when compared with the WT+AS+CML
group (p = 0.319, p = 0.261) (Figure 5).
The ASF/SF-2, TCRζ, ZAP-70 and FcεRIγ gene expression is
correlated in CML
ASF/SF-2 regulates TCRζ expression by binding to the
TCRζ 3’-UTR and down-regulating the alternatively-
spliced TCRζ 3’-UTR isoform. To further investigate the
mechanism for lower TCRζ expression in CML, we ana-
lyzed correlations between the relative ASF/SF-2, TCRζ,
ZAP-70 and FcεRIγ gene expression levels. A negative-
correlation was observed between the expression level of
TCRζ and ASF/SF-2 expression, but the difference was
Figure 4 The expression level of the ASF/SF-2, TCRζ, ZAP-70and FcεRIγ genes in the CML, CML-CR and healthy control groups (HI).
A: ASF/SF-2; B: FcεRIγ; C: TCRζ; and D: ZAP-70.
Figure 5 Differential expression pattern of the ASF/SF-2, TCRζ, ZAP-70 and FcεRIγ genes in the WT+AS- and WT+AS+CML groups.
A: ASF/SF-2; B: FcεRIγ; C: TCRζ; and D: ZAP-70.
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trast, the negative correlation between these genes was lost
in the CML-CR and CML groups (r = 0.001, p = 0.997;
r = 0.076, p = 0.642, respectively). When we further ana-
lyzed the correlation of the TCRζ and ASF/SF-2 gene
expression in the WT+AS- and WT+AS+ CML groups, we
found that a similar negative-correlation could be observed
in the WT+AS+ CML group (r = −0.17, p = 0.407), and
no correlation was observed in the WT+AS- CML group
(r =0.198, p = 0.497) (Figure 6).
Similar to a previous finding [36], a negative correl-
ation between the level of TCRζ and FcεRIγ gene ex-
pression was found in the healthy group, though the
difference was not statistically significant (r = −0.218,
p = 0.454), and this negative correlation was lost in the
CML group (r = 0.076, p = 0.642); however, the
negative-correlation remained in the WT+AS+ CML
group (r = −0.066, p = 0.748), and no correlation was
observed between these genes in the WT+AS- CML group
(r =0.165, p = 0.573). In contrast, a significant positive cor-
relation of the expression of both genes was found in the
CML-CR group (r = 0.473, p = 0.026) (Figure 7).
The expression correlation of the TCRζ and ZAP-70
genes was analyzed, and a significant positive correl-
ation was found in the healthy control, CML-CR and
CML groups (r = 0.600, p = 0.023; r = 0.637, p = 0.001;
and r = 0.460, p = 0.003, respectively). The same resultFigure 6 Correlation analysis of the TCRζ and ASF/SF-2 genes. A: Heal
CML group.was also found in the WT+AS+ CML group (r =0.737,
p < 0.001), while no significant correlation was found in
the WT+AS- CML group (r =0.320, p = 0.265) (Figure 8).
A significant positive correlation of the ASF/SF-2 and
FcεRIγ expression level was found in the healthy con-
trol and CML groups (r = 0.822 p < 0.001 and r = 0.334,
p = 0.035, respectively).
Discussion
Defects inTCR/CD3 signaling in CML
The TCR/CD3 complex plays a central role in T cell ac-
tivation, and the alteration of any subunits in the com-
plex may change the T cell activation level [7-10]. An
abnormal TCR repertoire, lower thymic output function
and lower CD3 gene expression have been described in
CML [2-6]. Alternative CD3 gene expression levels may
directly represent a characteristic of lower T cell activa-
tion [2-4]. In this study, the TCRζ expression level was
detected in 40 patients with chronic phase CML and
compared with CML in complete remission and healthy
individuals. Similar to our previous study, we found that
the TCRζ gene expression level in the CML group was
significantly lower than that in healthy controls [2], and
we further demonstrated that the TCRζ gene expression
level may be increased in patients with CML who
achieved complete remission. It is possible that the high
number of CML cells in the blood may have influencedthy controls; B: CML-CR group; C: WT+AS+ CML group; and D: WT+AS-
Figure 7 Correlation analysis of the TCRζ and FcεRIγ genes. A: Healthy controls; B: CML-CR group; C: WT+AS+ CML group; and D: WT+AS-
CML group.
Figure 8 Correlation analysis of the TCRζ and ZAP-70 genes. A: Healthy controls; B: CML-CR group; C: WT+AS+ CML group; and D: WT+AS-
CML group.
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strated decreased expression of the gene and protein en-
coding the TCRζ chain in purified CD3 + T cells in
chronic phase CML by quantitative real-time PCR and
FCM, respectively [37]. Thus, we used PMBC samples as
a simple method to analyze the expression characteris-
tics of the TCRζ chain and its related genes.
Unlike the TCRζ chain, which mediates signaling
through ZAP-70, FcεRIγ mediates signaling by associa-
ting with the phosphorylated protein kinase Syk, which
is 100-fold more potent than ZAP-70 and is preferen-
tially recruited to the FcεRIγ receptor [12,38-40]. Thus,
FcεRIγ may substitute for deficiencies in the TCRζ chain.
In this study, we analyzed the FcεRIγ gene expression
level and its correlation with TCRζ gene expression in
patients with CML. As expected, the FcεRIγ expression
level was significantly increased in patients with CML,
while its expression level was lower in patients who
achieved complete remission. These data suggest that, in
the context of CD3ζ down-regulation, FcεRIγ expression
in CML is up-regulated to contribute to TCR signaling
transduction in a manner similar to that of the con-
served functional ITAM motif, which is a different im-
mune status than that found in CLL, where the FcεRIγ
expression level was not up-regulated and was not cor-
related with the TCRζ expression level [36]. However,
FcεRIγ expression level did not demonstrate negative
correlation with TCRζ expression level in patients with
CML, suggesting that apparent defects in T cell-mediated
immunity are involved in alternative immune regulation
in CML. When we further analyzed the correlation in the
WT+AS+ and WT+AS- CML groups, we found that the
negative-correlation remained in WT+AS+ CML group,
and by combining the gene expression characteristics of
the WT+AS- CML group, it is thought that the defects in
immune regulation is apparent in the WT+AS- CML
group due to the differential distribution of TCRζ-3′UTR
spliceosomes. An interesting and significant positive cor-
relation between the expression of TCRζ and FcεRIγ genes
was found in the CML-CR group, and whether this is the
result of an abnormal immune regulation status rather
than immunodeficiency in patients with CML-CR remains
an open question.
It is well known, ZAP-70 is a downstream factor that
transduces TCR signals [41]. In this study, the finding of a
significant positive correlation between the expression level
of the TCRζ and ZAP-70 genes in the healthy control,
CML-CR and CML groups further supports the correl-
ation of the TCRζ and ZAP-70 genes in T cell activation.
The molecular mechanism of decreased TCRζ expression
in CML
A lower transduction of the TCR signal may be a com-
mon feature in hematological malignancies [36]. Theabsence of the TCRζ chain not only influences the TCR
expression on the cell membrane and the number of
single-positive (CD4+ or CD8+) circulating T cells, it
also impairs the proliferative response and mature T cell
activation level [42,43]. However, the mechanism of
TCRζ deficiency in T cells in patients with cancer is un-
clear. To gain insight into the molecular mechanism of
TCRζ deficiency in CML, we analyzed the distribution of
the TCRζ 3'-UTR isoforms, which contribute to the
regulation of TCRζ expression [19], and the ASF/SF-2
gene expression level, which regulates the alternative
splicing of eukaryotic genes.
In general, the TCRζ mRNA stability is mainly in-
fluenced by its downstream 3'-UTR. While the 906 bp
WT 3'-UTR plays an important role in TCRζ transcript
stability, the 344 bp alternatively spliced 3'-UTRsignifi-
cantly influences the generation of the TCRζ [22,23].
Interestingly, while we found that 35% of the CML sam-
ples in this study contained only the wild type TCRζ 3'-
UTR isoform, the wild type and alternatively spliced
TCRζ3'-UTRs isoform could be detected in all healthy
individual and CML-CR samples. These results may ac-
count for the feedback regulation of the immune system
in certain CML cases. Moreover, samples that contained
only the wild type TCRζ 3'-UTR isoform demonstrated a
high expression level for the ASF/SF-2, FcεRIγ, TCRζ
and ZAP-70 genes, and based on this finding, we tried
to characterized the different CML subgroups using the
different expression patterns of the TCR signaling com-
ponents. A definitive characteristic was found when
comparing the gene expression pattern of the ASF/SF-2,
FcεRIγ, TCRζ and ZAP-70 genes in the WT+AS-and
WT+AS+ CML groups.
The involvement of ASF/SF2 in the post-transcriptional
regulation of TCRζ was described in T cells from patients
with SLE. ASF/SF2 binds to the 3'-UTR of the TCRζ
mRNA and regulates a shift in alternative splicing from
the AS to the WT isoform, which modulates TCRζ protein
expression [19]. Therefore, a higher ASF/SF2 expression
level is correlated with a higher WT TCRζ3'-UTR expres-
sion level, which results in a higher TCRζ protein expres-
sion level. In this study, a significantly higher ASF/SF2
expression level was found in patients with CML who had
a lower TCRζ level, prompting the question of whether
there is feedback regulation in patients with CML similar
to that for the enhanced FcεRIγ expression level. However,
this feedback regulation was unable to recover the TCRζ
expression level. Interestingly, significantly higher ASF/
SF2 expression was found in the WT+AS-group as com-
pared with the WT+AS+CML group, a result that is in
agreement with the biological findings. No study has
reported similar results; thus, further investigation of more
samples with outcome follow up for patients with CML is
required in future studies.
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attempting to provide a global gene expression profile of
the TCRζ related genes: FcεRIγ, ASF/SF-2 and ZAP-70,
and the distribution characteristics of the TCRζ 3'-UTR
isoforms in de novo CML and CML-CR patients with
TCRζ defective. The preliminary data may indicate that
defective TCRζ expression may be characterized in the
WT+AS- and WT+AS+ CML subgroups with different
gene expression patterns. The TCRζ 3'-UTR alternative
splicing characteristics may be a novel immunological
marker for the evaluation of the CML immune status.
Moreover, ASF/SF-2 may also be a target for regulation by
the immune system to overcome immunodeficiency in
CML.
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